SK Chemical took approval of an anti-coagulation drug.

Published: 2004-06-09 06:58:00

Updated: 2004-06-09 06:58:00

SK Chemical and SK Pharmaceutical secured the KFDA approval of "Hootan", an anti-coagulation drug, for the treatment of blood coagulation and thrombo-embolism for patients on blood dialysis and acute pancreatitis, on June 1. Hootan will be sold in Korea under the technical licence agreement with ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK